Sulmazole (BioDeep_00000009552)

 

Secondary id: BioDeep_00001874002

human metabolite blood metabolite


代谢物信息卡片


2-[2-Methoxy-4-(methylsulphinyl)phenyl]-3H-imidazo[4,5-b]pyridine

化学式: C14H13N3O2S (287.0728)
中文名称: 苏咪唑
谱图信息: 最多检出来源 Mus musculus(blood) 50%

分子结构信息

SMILES: COC1=C(C=CC(=C1)S(=O)C)C2=NC3=C(N2)C=CC=N3
InChI: InChI=1S/C14H13N3O2S/c1-19-12-8-9(20(2)18)5-6-10(12)13-16-11-4-3-7-15-14(11)17-13/h3-8H,1-2H3,(H,15,16,17)

描述信息

C78274 - Agent Affecting Cardiovascular System > C78322 - Cardiotonic Agent
D004791 - Enzyme Inhibitors > D010726 - Phosphodiesterase Inhibitors
D020011 - Protective Agents > D002316 - Cardiotonic Agents
D002317 - Cardiovascular Agents

同义名列表

14 个代谢物同义名

2-[2-Methoxy-4-(methylsulphinyl)phenyl]-3H-imidazo[4,5-b]pyridine; 2-[2-Methoxy-4-(methylsulfinyl)phenyl]-3H-imidazo[4,5-b]pyridine; 2-(4-methanesulfinyl-2-methoxyphenyl)-1H-imidazo[4,5-b]pyridine; 2-((2-Methoxy-4-methylsulfinyl)phenyl)-H-imidazo(4,5-b)pyridine; AR-L 115 BS; Sulmazolum; Isomazole; sulmazole; BW a746c; Sulmazol; BWA746c; AR-L115; Vardax; Sulmazole



数据库引用编号

14 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 6 ADA, AXIN2, CYP1A1, MYLK, MYLK3, PRKX
Peripheral membrane protein 2 ADA, CYP1A1
Endoplasmic reticulum membrane 1 CYP1A1
Nucleus 3 AXIN2, CIART, PRKX
cytosol 4 ADA, AXIN2, MYLK, MYLK3
dendrite 1 ADORA1
centrosome 1 AXIN2
nucleoplasm 2 ATP2B1, PRKX
Cell membrane 3 ADA, ADORA1, ATP2B1
Cleavage furrow 1 MYLK
lamellipodium 1 MYLK
Multi-pass membrane protein 2 ADORA1, ATP2B1
Synapse 3 ADORA1, ATP2B1, MYLK
cell junction 1 ADA
cell surface 1 ADA
glutamatergic synapse 2 ATP2B1, TNC
mitochondrial inner membrane 1 CYP1A1
neuronal cell body 1 ADORA1
presynaptic membrane 2 ADORA1, ATP2B1
Lysosome 1 ADA
plasma membrane 6 ADA, ADORA1, ATP2B1, AXIN2, GCG, MYLK
presynaptic active zone 1 ADORA1
synaptic vesicle membrane 1 ATP2B1
terminal bouton 1 ADORA1
Membrane 3 ADA, ATP2B1, TNC
basolateral plasma membrane 2 ADORA1, ATP2B1
extracellular exosome 1 ATP2B1
extracellular space 2 GCG, TNC
mitochondrion 1 CYP1A1
intracellular membrane-bounded organelle 2 ATP2B1, CYP1A1
Microsome membrane 1 CYP1A1
Secreted 1 GCG
extracellular region 2 GCG, TNC
Extracellular side 1 ADA
Cytoplasmic vesicle lumen 1 ADA
anchoring junction 1 ADA
Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane 1 ATP2B1
external side of plasma membrane 1 ADA
Secreted, extracellular space, extracellular matrix 1 TNC
actin cytoskeleton 2 MYLK, MYLK3
dendritic spine 1 ADORA1
beta-catenin destruction complex 1 AXIN2
postsynaptic membrane 1 ADORA1
Cell projection, lamellipodium 1 MYLK
Mitochondrion inner membrane 1 CYP1A1
focal adhesion 1 TNC
axolemma 1 ADORA1
basement membrane 1 TNC
Nucleus, PML body 1 CIART
PML body 1 CIART
collagen-containing extracellular matrix 1 TNC
lateral plasma membrane 1 ATP2B1
cell projection 1 ATP2B1
Basolateral cell membrane 1 ATP2B1
Presynaptic cell membrane 1 ATP2B1
stress fiber 1 MYLK
secretory granule lumen 1 GCG
endoplasmic reticulum lumen 2 GCG, TNC
immunological synapse 1 ATP2B1
calyx of Held 1 ADORA1
Cytoplasm, cytoskeleton, stress fiber 1 MYLK
extracellular matrix of synaptic cleft 1 TNC
interstitial matrix 1 TNC
[Glucagon-like peptide 1]: Secreted 1 GCG
asymmetric synapse 1 ADORA1
photoreceptor ribbon synapse 1 ATP2B1
tenascin complex 1 TNC
perisynaptic extracellular matrix 1 TNC


文献列表

  • Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology. 2019 11; 96(5):629-640. doi: 10.1124/mol.119.115964. [PMID: 31515284]
  • R Sitsapesan, A J Williams. Regulation of the gating of the sheep cardiac sarcoplasmic reticulum Ca(2+)-release channel by luminal Ca2+. The Journal of membrane biology. 1994 Feb; 137(3):215-26. doi: 10.1007/bf00232590. [PMID: 8182731]
  • P Schneider. Drug-induced lysosomal disorders in laboratory animals: new substances acting on lysosomes. Archives of toxicology. 1992; 66(1):23-33. doi: 10.1007/bf02307266. [PMID: 1349805]
  • J R Woodworth, A F Delong, A F Fasola, S Oldham. Isomazole disposition in man as a function of dose and route of administration. Biopharmaceutics & drug disposition. 1991 Dec; 12(9):673-86. doi: 10.1002/bdd.2510120905. [PMID: 1790312]
  • J R Woodworth, A F DeLong, A F Fasola, S Oldham. 14C-isomazole disposition in man after oral administration. Pharmaceutical research. 1991 Nov; 8(11):1413-7. doi: 10.1023/a:1015857324838. [PMID: 1798679]
  • S R Holmberg, A J Williams. The cardiac sarcoplasmic reticulum calcium-release channel: modulation of ryanodine binding and single-channel activity. Biochimica et biophysica acta. 1990 Feb; 1022(2):187-93. doi: 10.1016/0005-2736(90)90113-3. [PMID: 2155020]
  • G E Sandusky, R B Franklin, J R Means. Acute, subchronic, and chronic toxicity of the cardiotonic isomazole in rats. Fundamental and applied toxicology : official journal of the Society of Toxicology. 1989 Oct; 13(3):409-17. doi: 10.1016/0272-0590(89)90278-9. [PMID: 2612774]
  • J R Means, R B Franklin, G E Sandusky. Toxicological evaluation of the cardiotonic isomazole in the dog. Fundamental and applied toxicology : official journal of the Society of Toxicology. 1989 Oct; 13(3):418-28. doi: 10.1016/0272-0590(89)90279-0. [PMID: 2612775]
  • J S Hayes, V L Wyss, H C Wilson, D W Robertson, R F Kauffman. Molecular basis for the in vitro and in vivo cardiotonic activities of AR-L100. The Journal of pharmacology and experimental therapeutics. 1986 Nov; 239(2):375-81. doi: . [PMID: 3021955]
  • J R Bernstein, R B Franklin. High-performance liquid chromatographic assay of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo-[4,5-c] pyridine hydrochloride, a potent cardiotonic agent, and two metabolites in plasma. Journal of chromatography. 1985 Jul; 342(1):228-33. doi: 10.1016/s0378-4347(00)84509-0. [PMID: 3840172]
  • A Walland. Investigation into the inotropic mechanisms of sulmazole. Arzneimittel-Forschung. 1985; 35(1A):369-76. doi: . [PMID: 4039176]
  • D el Allaf, V D'Orio, J Carlier. The new inotropic phosphodiesterase inhibitors. Archives internationales de physiologie et de biochimie. 1984 Nov; 92(4):S69-79. doi: 10.3109/13813458409071165. [PMID: 6085243]
  • F Hagemeijer, A Segers, A Schelling. Cardiovascular effects of sulmazol administered intravenously to patients with severe heart failure. European heart journal. 1984 Feb; 5(2):158-67. doi: 10.1093/oxfordjournals.eurheartj.a061626. [PMID: 6723686]
  • W Roth. Rapid, sensitive and fully automated high-performance liquid chromatographic assay with fluorescence detection for sulmazole and metabolites. Journal of chromatography. 1983 Dec; 278(2):347-57. doi: 10.1016/s0378-4347(00)84794-5. [PMID: 6668315]
  • M Renard, P Jacobs, P Mols, C Melot, A Dresse, R Bernard. The effective plasma concentrations of sulmazol (AR-L 115 BS) on haemodynamics in chronic heart failure. British journal of clinical pharmacology. 1983 Sep; 16(3):313-8. doi: 10.1111/j.1365-2125.1983.tb02167.x. [PMID: 6626424]
  • E R Garrett, W Roth. Nonlinear pharmacokinetics of the new positive inotropic agent sulmazole in the dog. Journal of pharmaceutical sciences. 1983 Feb; 72(2):105-16. doi: 10.1002/jps.2600720203. [PMID: 6834245]
  • E Maurer, W Klein, D Brandt. [Effect of sulmazol on left ventricular function in congestive cardiomyopathy]. Arzneimittel-Forschung. 1983; 33(5):760-3. doi: . [PMID: 6683555]
  • R J Solaro, J C Rüegg. Stimulation of Ca++ binding and ATPase activity of dog cardiac myofibrils by AR-L 115BS, a novel cardiotonic agent. Circulation research. 1982 Sep; 51(3):290-4. doi: 10.1161/01.res.51.3.290. [PMID: 6214330]
  • V Ceña, J Frias, A G García, M C Molinos, G P Nicolás, P Sánchez-García. Effects of the cardiotonic drug ARL-115 on the release of noradrenaline from the cat atrium, the binding of 3H-ouabain to plasma membranes and the movements of calcium in mitochondria. Naunyn-Schmiedeberg's archives of pharmacology. 1982 Sep; 320(3):255-9. doi: 10.1007/bf00510137. [PMID: 7133155]
  • H Pouleur, M F Rousseau, H van Mechelen, L Roncoroni, A Ries, A A Charlier. Cardiovascular effects of AR-L115 BS in conscious dogs with and without chronic congestive heart failure. Journal of cardiovascular pharmacology. 1982 May; 4(3):409-18. doi: 10.1097/00005344-198205000-00011. [PMID: 6177937]
  • P D Verdouw, J M Hartog, A M Ruggeman. Systemic and regional myocardial responses to AR-L 115 BS, a positive inotropic imidazo-pyridine, in the absence or in the presence of the bradycardiac action of alinidine. Basic research in cardiology. 1981 May; 76(3):328-43. doi: 10.1007/bf01907776. [PMID: 7271723]
  • U Busch. [Comparison of blood levels, excretion and metabolite pattern in rats non-pretreated and pretreated with subacute doses of AR-L 115 BS]. Arzneimittel-Forschung. 1981; 31(1a):209-12. doi: . [PMID: 7195223]
  • P Schneider, M Bauer, A Eckenfels, H Lehmann, L Lützen, H Ueberberg. [Animal studies on the tolerability of AR-L 115 BS (author's transl)]. Arzneimittel-Forschung. 1981; 31(1a):226-32. doi: . [PMID: 7195227]
  • B D Cameron, G H Draffan, J P Dunsire, A Zimmer. The absorption, metabolism and excretion of (14C)-AR-L 115 BS in the baboon. Arzneimittel-Forschung. 1981; 31(1a):217-20. doi: NULL. [PMID: 7195225]
  • J Mierau. [Pharmacokinetics of AR-L 115 BS in rhesus monkeys (author's transl)]. Arzneimittel-Forschung. 1981; 31(1a):221-5. doi: NULL. [PMID: 7195226]
  • U Busch. [Pharmacokinetics of AR-L 115 BS in the rat (author's transl)]. Arzneimittel-Forschung. 1981; 31(1a):204-9. doi: NULL. [PMID: 7195222]
  • W Roth, A Prox, A Reuter, J Schmid, A Zimmer, H Zipp. [AR-L 115 BS, comparison of human metabolite pattern and biotransformation with other species]. Arzneimittel-Forschung. 1981; 31(1a):232-5. doi: NULL. [PMID: 7195228]
  • W Roth, A Zimmer, U Busch. [Human pharmacokinetics of AR-L 115 BS (author's transl)]. Arzneimittel-Forschung. 1981; 31(1a):236-9. doi: NULL. [PMID: 7195229]
  • A Zimmer, R Hammer. [Pharmacokinetics of AR-L 115 BS in rabbits and dogs]. Arzneimittel-Forschung. 1981; 31(1a):212-6. doi: NULL. [PMID: 7195224]